Back to Journals » Cancer Management and Research » Volume 12

Accuracy of Sentinel Lymph Node Biopsy in Breast Cancer: Pitfalls in the Application of Single Tracers

Authors Yang J, Xu L, Liu P, Du Z, Chen J, Liang F, Long Q, Zhang D, Zeng H, Lv Q

Received 5 January 2020

Accepted for publication 13 April 2020

Published 1 May 2020 Volume 2020:12 Pages 3045—3051

DOI https://doi.org/10.2147/CMAR.S244806

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Xueqiong Zhu


Jiqiao Yang,1,2 Li Xu,1 Pengcheng Liu,1 Zhenggui Du,1 Jie Chen,1 Faqing Liang,1 Quanyi Long,1 Di Zhang,1,3 Helin Zeng,1 Qing Lv1

1Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 3Cancer Research Institute, Kanazawa University, Kanazawa, Japan

Correspondence: Qing Lv
Department of Breast Surgery, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu 610041, People’s Republic of China
Tel +86-2885422873
Email lvqingwestchina@163.com

Background: Radioisotopes and blue dyes are used as dual tracers in the current gold standard procedure of sentinel lymph node (SLN) biopsy (SLNB) performed for breast cancer. However, the blue dye or the radioisotope as a single tracer is also being applied in some institutes. We aimed to explore the risk factors for the miss-detection of SLNs with the radioisotope and the blue dye and to describe the distribution of SLNs missed by each tracer.
Patients and Methods: Patients undergoing SLNB with radioisotope and blue dye as dual mapping agents were enrolled between August 2010 and August 2018. Radioactivity count, blue dye staining status, and size and location of each SLN were prospectively documented.
Results: In total, 2382 SLNs from 1010 patients were included for statistical analyses. The sentinel node identification rate was 100% for dual tracers, 99.4% for radioisotope, and 89.1% for blue dye. SLN identification using the blue dye was more likely to fail in patients undergoing breast-conserving surgery (p < 0.001) and mastectomy with reconstruction (p = 0.005). Furthermore, miss-detection was significantly more frequent in smaller and uninvolved nodes. Among all SLNs, 8.2% were located in level II and one was in level III. Notably, single tracer of blue dye tended to fail in the detection of lymph nodes in higher levels (p < 0.001).
Conclusion: This study explored the association between features and the incidence of the failure to detect SLNs using radioisotope and blue dye. The locations of the miss-detected SLNs are demonstrated to provide a reference for SLNBs conducted using blue dye or radioisotope as a single tracer.

Keywords: breast cancer, sentinel lymph node, radioisotope, blue dye, single tracer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]